Apellis Pharma
Apellis Pharmaceuticals, often referred to simply as Apellis, is a leading biopharmaceutical company headquartered in the United States. Founded in 2009, the company has made significant strides in the field of complement biology, focusing on innovative therapies for rare diseases and serious conditions. With a strong operational presence in North America and Europe, Apellis is dedicated to transforming the treatment landscape for patients with unmet medical needs. The company’s flagship product, pegcetacoplan, is a groundbreaking therapy designed to address conditions such as paroxysmal nocturnal haemoglobinuria (PNH) and geographic atrophy (GA) associated with age-related macular degeneration. Apellis stands out in the industry for its commitment to advancing complement inhibition, positioning itself as a pioneer in this specialised area. With a robust pipeline and a focus on patient-centric solutions, Apellis Pharmaceuticals continues to solidify its reputation as a key player in the biopharmaceutical sector.
DitchCarbon Score
How does Apellis Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Education Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Apellis Pharma's score of 20 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Apellis Pharma's reported carbon emissions
Apellis Pharma, headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor specific reduction targets or initiatives outlined in their climate commitments. Without concrete figures or defined goals, it is challenging to assess their current impact on climate change or their strategic approach to reducing carbon emissions. In the broader context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and setting ambitious targets to reduce their carbon footprints. However, Apellis Pharma's specific commitments and actions in this area remain unclear. As the industry evolves, it will be important for Apellis to establish measurable goals and transparent reporting to align with global climate initiatives and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Apellis Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
